The aim of our financial reporting is to create transparency by providing comprehensive information. The figures and information give an overview of the Group's economic situation. Like the annual fiscal statements, the quarterly and half-year financial statements of the Biotest Group are prepared in accordance with the standards issued by the International Accounting Standards Board (IASB), London. For more information, you may also refer to presentations.
Sustainability
Biotest is committed to its responsibility to manufacture and market vital medicines from human blood plasma with the HIGHEST SAFETY, QUALITY and EFFICIENCY in a CLIMATE-FRIENDLY WAY, while providing sustainable benefits to society, patients, employees and shareholders on our path to carbon neutrality by 2035.
GoFuture
Following our vision "Go Future", the management team committed to the goal of complete climate neutrality by 2035.
Sustainability in BNL
The commercial production of our plant “Biotest Next Level” is an important step on our way to a more sustainable manufacturing. This plant will make it possible for us to produce immunoglobulins and other plasma products more sustainably than before – at a consistently high quality level!
Sustainability report according to German sustainability code (DNK)
In our current Sustainability Report we give insights into our advanced sustainability strategy and transparently document the company’s sustainability-related achievements in detail.
Suppliers Code of Conduct
Commitment to Sustainibility
Biotest is committed to responsible corporate governance in accordance with internationally recognized standards, in particular the Universal Declaration of Human Rights of the United Nations (UN) as of below voluntary commitment.
Policy statement
The Supply Chain Due Diligence Act (LkSG) regulates corporate responsibility for compliance with human rights in global supply chains. This includes, for example, protection against child labor, the right to fair wages and protection of the environment.